+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Devic's Syndrome Treatment Market by Treatment (Corticosteroids, Immunosuppressants, Plasma Exchange (Plasmapheresis)), Distribution Channel (Clinics, Hospitals, Online Pharmacies), End User - Forecast 2024-2030

  • PDF Icon

    Report

  • 191 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5977777
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Devic's Syndrome Treatment Market grew from USD 210.53 million in 2023 to USD 220.27 million in 2024. It is expected to continue growing at a CAGR of 4.68%, reaching USD 290.03 million by 2030.

The condition involves the immune system attacking healthy cells and can result in varying degrees of blindness and paralysis. Treatment strategies typically aim to manage symptoms and prevent relapses. Rising awareness of Devic's Syndrome globally through education and advocacy campaigns helps in early diagnosis and treatment. Improvements in healthcare infrastructure and accessibility allow more patients to receive timely and appropriate treatment, thereby increasing the adoption of treatments for Devic's Syndrome. However, the possibility of side effects and the inability of existing treatments to effectively target and manage Devic's Syndrome can reduce patient trust in the healthcare solution. Moreover, the rarity of Devic's Syndrome complicates research funding and drug development, often leaving this area less explored than more prevalent diseases. Exploring gene therapy could offer new ways to treat or possibly cure Devic's Syndrome in the future. Creating personalized treatment plans based on genetic profiles could improve treatment outcomes.

Regional Insights

In the Americas region, particularly in the United States and Canada, treatment options for Devic's Syndrome have evolved significantly with recent approvals of targeted therapies. A robust healthcare infrastructure and significant insurance coverage of several diseases have also created a favorable landscape for patients to access treatment for Devic's Syndrome. Patient advocacy groups play a crucial role in lobbying for insurance coverage and funding for research into new treatments. Investment in research is robust and supported by government bodies such as the National Institutes of Health and private enterprises. European Union countries share a commitment under EU regulations to support research and development in the field of rare diseases, including Devic's Syndrome. European Medicines Agency(EMA) approvals for new treatments are critical in defining consumer access across Europe. Patient access schemes and governmental funding significantly impact consumer purchasing behaviors, as treatments can be expensive. APAC's rapidly expanding healthcare system and increased investment in healthcare from both government and private sectors include a focus on rare diseases. Recent patents in APAC suggest a growing interest in developing novel treatments for conditions such as Devic's Syndrome, supported by state-funded programs and initiatives aimed at boosting biotechnology innovations.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Devic's Syndrome Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Growing incidences of Devic’s Syndrome across the world
  • Efforts to raise awareness for neurological conditions and the emergence of advocacy groups
  • Favorable regulatory approvals and government initiatives to ensure access to Devic’s syndrome treatments

Market Restraints

  • Complexity of the disease and the inability of treatments to tackle Devic’s Syndrome

Market Opportunities

  • Ongoing initiatives to improve the efficacy and safety of Devic’s Syndrome treatment solutions
  • Patient preference for personalized and specific treatment strategies

Market Challenges

  • Possibility of side effects of the treatment solutions for Devic’s Syndrome

Market Segmentation Analysis

  • Treatment: Utilization of corticosteroids for Devic's Syndrome due to their effectiveness in rapidly controlling inflammation
  • End User: Development of a comprehensive Devic’s Syndrome treatment plans for adult patients

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Devic's Syndrome Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Devic's Syndrome Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves Ultomiris for Neuromyelitis Optica Spectrum Disorder, Expanding Its Therapeutic Scope

The FDA has approved Ultomiris (ravulizumab-cwvz) for treating adult patients with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-aquaporin-4 (AQP4) antibodies. This decision was supported by data from the phase 3 CHAMPION-NMOSD trial. Ultomiris, a long-acting C5 complement inhibitor, is also used to treat other serious conditions such as generalized myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome, highlighting its versatility in managing autoimmune and hematologic disorders.

Health Canada Approves UPLIZNA for Adults with NMOSD

Horizon Therapeutics, a subsidiary of Amgen, announced that UPLIZNA (inebilizumab for injection) received approval from Health Canada. This approval allows it to be used as a single-agent treatment for adult patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD) who test positive for AQP4-IgG, a critical identifier in this rare, debilitating autoimmune condition. NMOSD primarily causes severe inflammation within the central nervous system, leading to recurrent, serious attacks that can result in permanent disabilities such as vision loss and paralysis.

Chugai Pharmaceutical’s Enspryng Launches in Taiwan for NMOSD Patients

Chugai Pharma Taiwan Ltd., a subsidiary of Chugai Pharmaceutical Co., Ltd., introduced Enspryng in Taiwan. This drug is tailored for adults and adolescents aged 12 and above who test positive for the anti-aquaporin-4 (AQP4) antibody, targeting neuromyelitis optica spectrum disorder (NMOSD). Earlier, the Ministry of Health and Welfare recognized Enspryng as an orphan drug, followed by its approval from the Taiwan Food and Drug Administration. This introduction marks Enspryng as a dedicated treatment for this patient group in Taiwan, showcasing a significant advancement in NMOSD care within the region.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Devic's Syndrome Treatment Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Devic's Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare, Inc., Alexion Pharmaceuticals, Inc by AstraZeneca PLC, Anant Pharmaceuticals Pvt. Ltd., Apple Pharmaceuticals, Cadila Pharmaceuticals Limited, Chugai Pharma Taiwan Ltd., Conscientia Industrial Co., Ltd, Evidentic GmbH, F. Hoffmann-La Roche Ltd, Healthy Life Pharma Pvt. Ltd., Horizon Therapeutics plc by Amgen, Inc., LEXICARE PHARMA PVT. LTD., Merck KGaA, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics, Inc., Samsung Bioepis Co., Ltd. by Samsung Biologics, Teva Pharmaceutical Industries Ltd., TG Therapeutics, Inc., Thermo Fisher Scientific Inc., and West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC.

Market Segmentation & Coverage

This research report categorizes the Devic's Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment

  • Corticosteroids
  • Immunosuppressants
  • Plasma Exchange (Plasmapheresis)

Distribution Channel

  • Clinics
  • Hospitals
  • Online Pharmacies

End User

  • Adult Patients
  • Pediatric Patients

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidences of Devic’s Syndrome across the world
5.1.1.2. Efforts to raise awareness for neurological conditions and the emergence of advocacy groups
5.1.1.3. Favorable regulatory approvals and government initiatives to ensure access to Devic’s syndrome treatments
5.1.2. Restraints
5.1.2.1. Complexity of the disease and the inability of treatments to tackle Devic’s Syndrome
5.1.3. Opportunities
5.1.3.1. Ongoing initiatives to improve the efficacy and safety of Devic’s Syndrome treatment solutions
5.1.3.2. Patient preference for personalized and specific treatment strategies
5.1.4. Challenges
5.1.4.1. Possibility of side effects of the treatment solutions for Devic’s Syndrome
5.2. Market Segmentation Analysis
5.2.1. Treatment: Utilization of corticosteroids for Devic's Syndrome due to their effectiveness in rapidly controlling inflammation
5.2.2. End User: Development of a comprehensive Devic’s Syndrome treatment plans for adult patients
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Devic's Syndrome Treatment Market, by Treatment
6.1. Introduction
6.2. Corticosteroids
6.3. Immunosuppressants
6.4. Plasma Exchange (Plasmapheresis)
7. Devic's Syndrome Treatment Market, by Distribution Channel
7.1. Introduction
7.2. Clinics
7.3. Hospitals
7.4. Online Pharmacies
8. Devic's Syndrome Treatment Market, by End User
8.1. Introduction
8.2. Adult Patients
8.3. Pediatric Patients
9. Americas Devic's Syndrome Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Devic's Syndrome Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Devic's Syndrome Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. FDA Approves Ultomiris for Neuromyelitis Optica Spectrum Disorder, Expanding Its Therapeutic Scope
12.3.2. Health Canada Approves UPLIZNA for Adults with NMOSD
12.3.3. Chugai Pharmaceutical’s Enspryng Launches in Taiwan for NMOSD Patients
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. DEVIC'S SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. DEVIC'S SYNDROME TREATMENT MARKET DYNAMICS
FIGURE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. DEVIC'S SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE (PLASMAPHERESIS), BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE (PLASMAPHERESIS), BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 30. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 31. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 32. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 33. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 34. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 37. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 38. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 39. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 40. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 41. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 42. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 43. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 44. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 45. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 46. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 47. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 48. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 49. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 50. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 51. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 52. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 53. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 54. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 55. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 56. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 57. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 58. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 59. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 60. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 61. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 62. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 63. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 64. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 65. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 66. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 67. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 68. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 70. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 72. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 74. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 76. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 77. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 78. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 79. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 80. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 81. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 82. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 83. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 84. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 85. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 86. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 87. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 88. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 89. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 90. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 91. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 92. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 93. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 94. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 95. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 96. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 97. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 98. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 99. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 100. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 101. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 102. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 103. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 104. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 105. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 106. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 107. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 108. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 109. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 110. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 111. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 112. MALAYSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 113. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 114. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 115. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 116. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 117. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 118. PHILIPPINES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 119. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 120. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 121. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 122. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 123. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 124. SINGAPORE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 125. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 126. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 127. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 128. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 129. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 130. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 131. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 132. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 133. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 134. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 135. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 136. TAIWAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 137. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 138. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 139. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 140. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 141. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 142. THAILAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 143. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 144. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 145. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 146. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 147. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 148. VIETNAM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 157. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 158. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 159. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 160. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 161. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 162. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 163. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 164. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 165. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 166. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 167. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 168. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 169. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 170. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 171. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 172. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 173. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 174. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 175. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 176. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 177. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 178. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 179. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 180. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 181. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 182. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 183. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 184. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 185. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 186. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 187. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 188. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 189. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 190. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 191. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 192. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 193. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 194. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 195. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 196. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 197. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 198. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 199. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 200. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 201. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 202. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 203. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 204. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 205. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 206. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 207. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 208. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 209. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 210. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 211. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 212. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 213. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 214. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 215. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 216. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 217. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 218. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 219. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 220. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 221. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 222. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 223. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 224. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 225. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 226. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 227. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 228. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 229. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 230. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 231. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 232. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 233. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 234. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 236. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 238. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 240. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 242. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 244. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 246. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 247. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 248. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 249. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 250. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 251. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 252. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 253. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 254. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 255. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 256. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 257. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 258. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 259. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 260. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 261. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 262. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 263. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 264. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 265. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 266. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 267. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 268. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 269. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 270. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 278. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 280. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 282. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 283. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 284. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Accord Healthcare, Inc.
  • Alexion Pharmaceuticals, Inc by AstraZeneca PLC
  • Anant Pharmaceuticals Pvt. Ltd.
  • Apple Pharmaceuticals
  • Cadila Pharmaceuticals Limited
  • Chugai Pharma Taiwan Ltd.
  • Conscientia Industrial Co., Ltd
  • Evidentic GmbH
  • F. Hoffmann-La Roche Ltd
  • Healthy Life Pharma Pvt. Ltd.
  • Horizon Therapeutics plc by Amgen, Inc.
  • LEXICARE PHARMA PVT. LTD.
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Opexa Therapeutics, Inc.
  • Samsung Bioepis Co., Ltd. by Samsung Biologics
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • West-Ward Pharmaceuticals Corp. by Hikma Pharmaceuticals PLC

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages191
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 220.27 Million
Forecasted Market Value ( USD ) by 2030 $ 290.03 Million
Compound Annual Growth Rate4.6%
Regions CoveredGlobal

Related Topics

Related Reports

Neuromyelitis Optica - Pipeline Insight, 2024 - Product Image

Neuromyelitis Optica - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2024 - Product Image

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2024

  • Clinical Trials
  • 50 Pages
  • Global
From
Global Lennox-Gastaut Syndrome Treatment Market by Therapy Type (Non-Surgical Treatment, Surgery), Route of Administration (Oral, Parenteral), Distribution Channel, End Users - Forecast 2024-2030 - Product Image

Global Lennox-Gastaut Syndrome Treatment Market by Therapy Type (Non-Surgical Treatment, Surgery), Route of Administration (Oral, Parenteral), Distribution Channel, End Users - Forecast 2024-2030

  • Report
  • 186 Pages
  • Global
From
Global Guillain-Barre Syndrome Market by Type (Acute Inflammatory Demyelinating Polyneuropathy, Acute Motor & Sensory Axonal Neuropathy, Acute Motor Axonal Neuropathy), Treatment (Hydrotherapy, Medication, Physical Therapy), End-User - Forecast 2024-2030 - Product Image

Global Guillain-Barre Syndrome Market by Type (Acute Inflammatory Demyelinating Polyneuropathy, Acute Motor & Sensory Axonal Neuropathy, Acute Motor Axonal Neuropathy), Treatment (Hydrotherapy, Medication, Physical Therapy), End-User - Forecast 2024-2030

  • Report
  • 180 Pages
  • Global
From
Global Tourette Syndrome Treatment Market - Product Image

Global Tourette Syndrome Treatment Market

  • Report
  • 200 Pages
  • Global
From

About the Neuromyelitis Optica Drug Market

Neuromyelitis Optica (NMO) is a rare autoimmune disorder of the central nervous system (CNS) that affects the optic nerves and spinal cord. It is characterized by recurrent episodes of optic neuritis and transverse myelitis, which can lead to permanent vision loss and paralysis. Treatment of NMO is focused on reducing inflammation and preventing further damage to the CNS. Drugs used to treat NMO include corticosteroids, immunosuppressants, and monoclonal antibodies. Corticosteroids are used to reduce inflammation and prevent further damage to the CNS. Immunosuppressants are used to reduce the activity of the immune system and prevent further attacks. Monoclonal antibodies are used to target specific molecules involved in the autoimmune response. The NMO drug market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of NMO and the development of new treatments. Companies in the NMO drug market include Biogen, Alexion Pharmaceuticals, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.